Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant.
about
Comparison of transplant outcomes and economic costs between biosimilar and originator filgrastim in allogeneic hematopoietic stem cell transplantation.SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders.
P2860
Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Use of biosimilar filgrastim c ...... sibling allogeneic transplant.
@ast
Use of biosimilar filgrastim c ...... sibling allogeneic transplant.
@en
type
label
Use of biosimilar filgrastim c ...... sibling allogeneic transplant.
@ast
Use of biosimilar filgrastim c ...... sibling allogeneic transplant.
@en
prefLabel
Use of biosimilar filgrastim c ...... sibling allogeneic transplant.
@ast
Use of biosimilar filgrastim c ...... sibling allogeneic transplant.
@en
P2093
P2860
P356
P1476
Use of biosimilar filgrastim c ...... sibling allogeneic transplant.
@en
P2093
Barbara Davy
Joe Taylor
Maresa Farrell
Pippa Russell
Samir G Agrawal
Shab Uddin
P2860
P356
10.1177/2040620714565962
P577
2015-04-01T00:00:00Z